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One of the breakthrough discoveries of my work was uncovering a new 
physiological context for P-bodies. Indicated by a morphological transition and 
downregulation in EMT marker, E-cadherin, I observed a strong correlation 
between the induction of P-bodies and the induction of EMT. This evidence 
suggests a role for P-bodies in EMT and ultimately cancer metastasis. My future 
studies are designed to test this hypothesis in preclinical mouse models.  
DEAD box RNA helicase 6 (DDX6), is an RNA binding protein that plays 
an integral part in the formation of P-bodies and shown to be associated with 
miRNA repression (76, 80, 86). DDX6 is characterized by signature motifs (Asp-
Glu-Ala-Asp) which work in promoting the RNA-dependent ATPase and ATP-
dependent RNA helicase activities of the protein. DDX6 specifically has the 
ability to bind RNA, facilitate the hydrolysis of ATP in an RNA-dependent fashion, 
and unwind RNA duplexes. (135). DDX6 was found to be expressed in malignant 
human transformed cells deriving from tissues including brain, lung, and colon 
that normally contain little to no expression of DDX6 (136–138). These findings 
suggest DDX6 as a candidate proto-oncogene.  Using siRNA specific to DDX6 in 
	 78	
NMuMGs, I observed a reduction in P-body formation (Figure 5.1). Not only was 
P-body formation attenuated, knockdown cells exhibited a resistance to EMT 
(Figure 5.2). Therefore, I decided to use this approach in determining if P-bodies 
are necessary for metastasis.  
Luciferase-labeled 4T1 mouse mammary tumor cells (4T1.L4) will be used 
for investigating tumor metastasis. These cells were kindly provided by Dr. 
Michael Wendt. Using the cells, I have already generated DDX6 knockout 
luciferase-labeled 4T1 cells (4T1.L4 DDX6 KO). I intend to inject female BALB/c 
mice with these cells in the mammary fat pad and examine lung metastasis using 
bioluminescence imaging. This work is ongoing and the results from this 
experiment will give us some insight on the importance of P-bodies in tumor 




































































































Mesenchymal- epithelial transition is the reversion of cells in a 
mesenchymal state back to their original epithelial morphology. While EMT 
seems to be important for dissemination of cancer cells from the primary tumor; 
MET appears to be necessary for cancer cell colonization and macrometastasis 
at a new site. In a previous study, SYK mRNA levels were shown to be down 
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regulated as a result of EMT. I was able to confirm SYK loss in breast cancer 
cells at the protein level when EMT is induced. Although SYK expression is lost 
when EMT is induced, once the cells are allowed to recover and MET occurs, I 
observe SYK re-expression. I show that the inhibition of SYK activity inhibits 
these cells ability to revert back to an epithelial state upon the removal of EMT 
inducer, TGF-β. This observation correlates with the lack of autophagy occurring 
in these cells. The inhibition of SYK activity mimics the lack of autophagy, since 
autophagy also was shown to be necessary for MET to occur. This led to my 
hypothesis that SYK and autophagy are necessary for the establishment of tumor 
metastases.  To investigate this hypothesis, mouse models will need to be used.  
Similar to the experiment I described for investigating the role of P-bodies in 
breast cancer metastasis, we would use the same model, however the 4T1 cell 
lines will be generated to knockout SYK or an essential autophagy component 
like ATG7. We would examine these cells ability to establish new tumors in the 
lung using bioluminescence imaging. I postulate that the cells lacking SYK or 
ATG7 will not be able to colonize new tumor sites in the mice. The results of this 
experiment will begin to provide context to the stage dependency of SYK and 
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